Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · T. Rowe Price

T. Rowe Price Health Sciences Portfolio T. Rowe Price Health Sciences Portfolio (QAAGZX)

Ticker QAAGZX · Since 2000-12-29 · · Holdings as of Jun 30, 2026

Expense ratio
0.86%$86/yr per $10k
5-yr return
+4.1%annualized
1-yr return
+18.1%as of Dec 2025
Net assets
$751.7Mall share classes
Holdings
277

Bottom line

Is QAAGZX a good fund? The bottom line

QAAGZX is a share class of T. Rowe Price Health Sciences Portfolio, a managed health care sector ETF from T. Rowe Price.

Annual fees run 0.86% — about $86 a year on every $10,000 invested, cheaper than 56% of health care sector funds we track.

It returned +18.1% over one year, +4.1% a year over five years, +9.0% a year over ten (as of Dec 31, 2025, per its prospectus).

With $752 million in net assets and 277 holdings, its largest position is Eli Lilly & Co (14.1%) and the top 10 make up 47.3% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 80% top-holdings overlap).

What stands out

  • Broadly diversified (277 holdings)

Updated Nov 19, 2026

What QAAGZX invests in

The fund seeks long-term capital appreciation.

In the Summary Prospectus, and Sections 1 and 2 of the Prospectus, the disclosure under Principal Investment Strategies is supplemented as follows: The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.

From the fund's prospectus (filed Jun 30, 2026).

QAAGZX performance

Fund calendar-year total returns, 2016–2025 2016: −10.5%; 2017: +27.6%; 2018: +1.1%; 2019: +29.0%; 2020: +29.6%; 2021: +13.1%; 2022: −12.5%; 2023: +3.0%; 2024: +1.7%; 2025: +18.1% −10% 2016 +28% 2017 +1% 2018 +29% 2019 +30% 2020 +13% 2021 −12% 2022 +3% 2023 +2% 2024 +18% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
QAAGZX+18.1%+4.1%+9.0%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full QAAGZX performance history →

What QAAGZX costs

On a $10,000 investment, QAAGZX's 0.86% expense ratio costs about $86 a year. The prospectus estimates $1,061 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full QAAGZX fee table →

QAAGZX top 10 holdings

#Holding% of fund
1Eli Lilly & Co14.06%
2Johnson & Johnson6.64%
3Unitedhealth Group Inc5.88%
4Abbvie Inc5.12%
5Merck & Co. Inc.4.00%
6Gilead Sciences Inc2.79%
7Thermo Fisher Scientific Inc2.53%
8Vertex Pharmaceuticals Inc2.26%
9Bristol-myers Squibb Co2.12%
10Abbott Laboratories1.91%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 47.3% of the fund. See all top 25 holdings and asset mix →

Alternatives to QAAGZX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%80% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%79% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%79% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%77% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%58% Compare
SchwabSWHFX Schwab Health Care Fund0.8%73% Compare

More funds like QAAGZX →

QAAGZX FAQ

What is the expense ratio of QAAGZX?
QAAGZX's expense ratio is 0.86%, which works out to about $86 a year for every $10,000 invested. The prospectus estimates total costs of $1,061 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is QAAGZX a good investment?
It depends on your goals, but the data points to: broadly diversified (277 holdings). This is general information, not personalized advice.
What does QAAGZX hold?
QAAGZX's largest holdings are Eli Lilly & Co (14.1%), Johnson & Johnson (6.6%), Unitedhealth Group Inc (5.9%), Abbvie Inc (5.1%), Merck & Co. Inc. (4.0%). It holds 277 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is QAAGZX's 5-year return?
QAAGZX returned +4.1% a year over the five years ending Dec 31, 2025, and +9.0% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to QAAGZX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 80% with QAAGZX and charges 0.08%.
Who manages QAAGZX?
QAAGZX is offered by T. Rowe Price through T. Rowe Price Equity Series, Inc..